Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 287 - 301
Published: May 1, 2024
Language: Английский
Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: 23(9), P. 709 - 722
Published: July 4, 2024
Language: Английский
Citations
92
European Journal of Pharmaceutics and Biopharmaceutics, Journal Year: 2024, Volume and Issue: 198, P. 114266 - 114266
Published: March 16, 2024
Design of inhalable mRNA therapeutics is promising, because local administration in the respiratory tract minimally invasive and induces a response. However, several challenges related to via inhalation barriers have so far prevented progress inhaled therapeutics. Here, we investigated factors importance for lipid nanoparticle (LNP)-mediated delivery tract. We hypothesized that: (i) PEG-lipid content important providing colloidal stability during aerosolization mucosal delivery, (ii) influences expression lungs, (iii) route (nasal versus pulmonary) lungs. In this study, aimed optimize investigate effect on kinetics expression. Our results show that increasing improves process, but has negative impact transfection efficiency vitro. The protein vivo dependent administration, found pulmonary mRNA-LNPs mice longer than nasal administration. These demonstrate design system are achieving high
Language: Английский
Citations
21
Nucleosides Nucleotides & Nucleic Acids, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 25
Published: Jan. 13, 2025
The field of biomedical science has witnessed another milestone with the advent RNA-based therapeutics. This review explores three major RNA molecules, namely: messenger (mRNA), interference technology (RNAi), and Antisense Oligonucleotide (ASO), analyses U.S. Food Drug Administration drugs from 14 pharmaceutical companies in terms targeted genes, diseases types, clinical trials status, mode delivery, year production. Many such are clinically approved or pending approval by (FDA) alongside other leading agencies. Regarding diseases, this article emphasizes cancer therapy, genetic viral infections, two categories drug delivery systems include vectors nanoparticles. Despite tremendous progress made, key issues associated these stability, off-target activities payloads, efficiency cellular uptake, innovative need for engineering techniques modifications. transformative potential therapeutics role technologies addressing needs, paving way a new era precision medicine.
Language: Английский
Citations
3
Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)
Published: Jan. 17, 2025
Cytomegalovirus (CMV) is a leading cause of congenital infections and significant health complications in immunocompromised individuals. With no licensed CMV vaccine available, the development mRNA-1647 offers promising advancements prevention. We have reviewed results from Phase 1 2 clinical trials vaccine, demonstrating robust immune responses both seronegative seropositive participants. Vaccines exhibited significantly elevated neutralizing antibody titers against CMV, particularly fibroblast epithelial cells, with sustained lasting up to 18 months post-vaccination. The triggered strong T-cell memory B-cell responses, suggesting its potential for long-term protection infection. ongoing 3 CMVictory trial evaluates safety immunogenicity women childbearing age, preliminary data showing promise preventing transmission. This could reduce CMV-related morbidity mortality, newborns individuals, addressing critical unmet medical need.
Language: Английский
Citations
3
Journal of Chromatography A, Journal Year: 2025, Volume and Issue: unknown, P. 465724 - 465724
Published: Jan. 1, 2025
Language: Английский
Citations
3
Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13
Published: March 12, 2025
The advent of mRNA vaccines, accelerated by the global response to COVID-19 pandemic, marks a transformative shift in vaccine technology. In this article, we discuss development, current applications, and prospects vaccines for both prevention treatment infectious diseases oncology. By leveraging capacity encode antigens within host cells directly, provide versatile scalable platform suitable addressing broad spectrum pathogens tumor-specific antigens. We highlight recent advancements design, innovative delivery mechanisms, ongoing clinical trials, with particular emphasis on their efficacy combating diseases, such as COVID-19, Zika, influenza, well emerging potential cancer immunotherapy. also address critical challenges, including stability, optimization immune responses, broader issue accessibility. Finally, review strategies advancing next-generation aim overcoming limitations technology enhancing preventive therapeutic approaches oncological diseases.
Language: Английский
Citations
2
Advanced Materials, Journal Year: 2024, Volume and Issue: 36(30)
Published: April 28, 2024
Abstract In the realm of cancer therapy, spotlight is on nanoscale pharmaceutical delivery systems, especially polymer‐based nanoparticles, for their enhanced drug dissolution, extended presence in bloodstream, and precision targeting achieved via surface engineering. Leveraging amplified permeation retention phenomenon, these systems concentrate therapeutic agents within tumor tissues. Nonetheless, hurdles systemic toxicity, biological barriers, compatibility with living persist. Fluorinated polymers, distinguished by chemical idiosyncrasies, are poised extensive biomedical applications, notably stabilizing metabolism, augmenting lipophilicity, optimizing bioavailability. Material science heralds advent fluorinated polymers that, integrating fluorine atoms, unveil a suite merits: hydrophobic traits alkyl chains ward off lipid or protein disruption, carbon–fluorine bond's stability extends drug's lifecycle system, lower alkalinity coupled diminished ionic charge bolsters ability to traverse cellular membranes. This comprehensive review delves into utilization oncological pharmacotherapy, elucidating molecular architecture, synthetic pathways, functional attributes, alongside an exploration empirical strengths quandaries they encounter both experimental clinical settings.
Language: Английский
Citations
16
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Nov. 29, 2024
Language: Английский
Citations
14
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Oct. 4, 2024
Autoimmune disorders are characterized by aberrant T cell and B reactivity to the body's own components, resulting in tissue destruction organ dysfunction. diseases affect a wide range of people many parts world have become one major concerns public health. In recent years, there been substantial progress our understanding epidemiology, risk factors, pathogenesis mechanisms autoimmune diseases. Current approved therapeutic interventions for mainly non-specific immunomodulators may cause broad immunosuppression that leads serious adverse effects. To overcome limitations immunosuppressive drugs treating diseases, precise target-specific strategies urgently needed. date, significant advances made immune tolerance, offering new avenue developing antigen-specific immunotherapies These approaches shown great potential various preclinical animal models recently evaluated clinical trials. This review describes common manifestation with focus on typical including multiple sclerosis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, sjögren's syndrome. We discuss current therapeutics developed this field, highlight use nanomaterials mRNA vaccine techniques induce tolerance.
Language: Английский
Citations
13
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 372, P. 113 - 140
Published: June 15, 2024
Language: Английский
Citations
12